神经损伤诱导蛋白2在胶质瘤中的表达及其意义-东南大学学报医学版

神经损伤诱导蛋白2在胶质瘤中的表达及其意义

单位：广西壮族自治区桂东人民医院神经外科, 广西梧州 543001

分类号：R739.41

出版年·卷·期（页码）：2021·40·第四期（506-511）

摘要：

目的：探讨细胞黏附分子神经损伤诱导蛋白2（Ninjurin2）在胶质瘤中的表达及其意义。方法：采用免疫组化染色法检测88例胶质瘤组织和30例正常脑组织中Ninjurin2的表达，用COX多因素分析和Kaplan-Meier曲线分析胶质瘤患者的生存预后，蛋白印迹法检测人胶质瘤细胞系U251、U87、U373和正常胶质细胞系SVG中Ninjurin2的表达。取U251细胞，用Lipofectamine^® 2000试剂分别转染Ninjurin2 siRNA序列（Ninjurin2-siRNA组）、阴性对照序列（NC-siRNA组），细胞增殖实验评估两组细胞的增殖能力，肿瘤小室实验检测两组肿瘤细胞的侵袭能力。结果：胶质瘤组织中Ninjurin2蛋白高表达率为65.91%（58/88），高于正常脑组织的20.00%（6/30）（P<0.05）。COX多因素分析结果显示，术前卡氏评分（OR=2.312）、WHO分级（OR=2.008）、化疗（OR=1.600）和Ninjurin2（OR=2.816）是胶质瘤患者总生存期的独立影响因素（均P<0.05）。Ninjurin2高表达组中位生存时间为11个月，明显低于低表达组的19个月（P=0.004）。与SVG细胞比较，U251、U87和U373细胞中Ninjurin2蛋白相对表达量较高（均P<0.05）。与NC-siRNA组比较，Ninjurin2-siRNA组U251细胞增殖和侵袭能力明显下降（均P<0.05）。结论：Ninjurin2可能参与胶质瘤进展，Ninjurin2高表达与患者不良生存预后有关。

Objective: To investigate the expression and significance of cell adhesion molecule Ninjurin2 in gliomas. Methods: Immunohistochemical staining was used to detect the expression levels of Ninjurin2 in 88 glioma tissues and 30 normal brain tissues. COX multivariate analysis and Kaplan-Meier curve were adopted to analyze the survival prognosis of glioma patients. Western-blotting assay was used to determine the expression of Ninjurin2 in human glioma cell lines U251, U87, U373 and normal glial cell lines SVG. U251 cells were transferred into Ninjurin2 siRNA sequence(Ninjurin2-siRNA group) and negative control siRNA sequence(NC-siRNA group) with Lipotectamine respectively. Cell proliferation assay was used to evaluate the ability of cell proliferation in each group. The invasion and migration of cancer cells were detected by Transwell experiment in different groups. Results: The expression level of Ninjurin2 protein in glioma tissue was 65.91%(58/88), which was 20.00%(6/30) higher than that in normal brain tissue(P<0.05). COX multivariate analysis indicated that the preoperative Karnofsky score(OR=2.312), WHO classification(OR=2.008), chemotherapy(OR=1.600) and Ninjurin2(OR=2.816) were independent factors affecting the overall survival of glioma patients(P<0.05). Kaplan-Meier survival analysis results indicated that the median survival time of Ninjurin2 high expression group was 11 months, which was significantly lower than 19 months of low expression group(P=0.004). Compared with SVG cells, the expression of Ninjurin2 protein in U251, U87 and U373 cells was higher(all P<0.05). Compared with the NC-siRNA group, the proliferation and invasion ability of U251 cells in the Ninjurin2-siRNA group was significantly decreased(P<0.05). Conclusion: Ninjurin2 involves in the progression of glioma, and high expression of Ninjurin2 is associated with the poor survival prognosis of the patients.

参考文献：

[1] OBERNDORFER S, HUTTERER M.Palliative care in glioma management[J]. Curr Opin Oncol, 2019, 31(6):548-553.
[2] CHEN W, LEI C, LIU P, et al. Progress and prospects of recurrent glioma:a recent scientometric analysis of the web of science in 2019[J]. World Neurosurg, 2020, 134:e387-e399.
[3] ARAKI T, MILBRANDT J.Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth[J]. J Neurosci, 2000, 20(1):187-195.
[4] JING D, YINZHU L, JINJING P, et al. Targeting ninjurin 2 by miR-764 regulates hydrogen peroxide (H2O2)-induced neuronal cell death[J]. Biochem Biophys Res Commun, 2018, 505(4):1180-1188.
[5] LI G, ZHOU L N, YANG H, et al. Ninjurin 2 overexpression promotes human colorectal cancer cell growth in vitro and in vivo[J]. Aging(Albany NY), 2019, 11(19):8526-8541.
[6] FENG X, ZHANG L, KE S, et al. High expression of GPNMB indicates an unfavorable prognosis in glioma:combination of data from the GEO and CGGA databases and validation in tissue microarray[J]. Oncol Lett, 2020, 20(3):2356-2368.
[7] ZHOU Q, LIU J, QUAN J, et al. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma:a systematic review and meta-analysis[J]. Gene, 2018, 668:77-86.
[8] HARJUNPÄÄ H, LLORT A M, GUENTHER C, et al. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment[J]. Front Immunol, 2019, 10:1078-1085.
[9] WANG J, FA J, WANG P, et al. NINJ2-A novel regulator of endothelial inflammation and activation[J]. Cell Signal, 2017, 35:231-241.
[10] 梁峰.Ninj2通过影响胞内钙离子水平抑制GBM增殖[D].厦门:厦门大学, 2019.
[11] LIU L Q, FENG L F, NAN C R, et al. CREB3L1 and PTN expressions correlate with prognosis of brain glioma patients[J]. Biosci Rep, 2018, 38(3):1-9.
[12] LI Q, WU Q, LI Z, et al. LncRNA LINC00319 is associated with tumorigenesis and poor prognosis in glioma[J]. Eur J Pharmacol, 2019, 861:121-128.
[13] QI Y, DENG G, XU P, et al. HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma[J]. Oncol Rep, 2019, 42(6):2309-2322.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录